Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alnylam Pharmaceuticals has granted Shanghai GenePharma a non-exclusive world-wide license to manufacture and provide RNAi research products and services under the Kreutzer-Limmer patent family.
Subscribe to our email newsletter
This patent family, owned exclusively by Alnylam, covers fundamental aspects of the structure and uses of RNAi products including their use to mediate RNAi in mammalian cells and of RNAi-related mechanisms.
Peter Zhang, Chairman and CEO of Shanghai GenePharma, said: “This agreement with Alnylam reinforces our ability to become a leading global supplier of RNAi reagent products to the pharmaceutical and research community in China and worldwide. Access to the Kreutzer-Limmer patent estate allows us to augment our RNAi products, thereby strengthening our position in the life sciences marketplace.”